Some highlights from Formation Bio CEO & Co-Founder @BenjamineYLiu at this morning's panel discussion at @wef about how companies - and entire industries - are positioned to scale with AI in unprecedented ways. You can find the full recording here:

Tune in tomorrow @wef as our Co-Founder & CEO @BenjamineYLiu discusses the future of AI-driven organizations, together with: - @CNBC's @dan_murphy - @imbue_ai's @kanjun - @LeadEdgeCapital's Mitchell Green - @LatticeHQ's Sarah Franklin - @youdotcom's @RichardSocher

We're delighted to have contributed to this white paper published today by @wef and @ZSAssociates exploring AI’s potential to revolutionize clinical development. The themes explored in this paper align deeply with our mission to harness AI for transformative advances in drug development, working to ultimately bring new treatments to patients faster and more efficiently.

Our CDO @gavincorcoranmd will be presenting at @business's AI & Drug Development Forum next week in NYC! Learn more and register to attend here: Other presenters include: @OwkinScience @Certara @FlagshipPioneer @Clario @InSilicoMeds @Parexel

RT @skupor: Great example of a tangible AI use case in one of the most intractable problem areas - drug development. Congrats @formationbio

RT @AndrewE_Dunn: “If we think about all the drug development activities, we think there’s a Muse for everything,” Formation Bio CEO Benjam…

RT @BenjamineYLiu: Meet Muse, our latest AI innovation for drug development—a tool designed to optimize patient recruitment built together…

Meet Muse - our AI tool for patient recruitment strategy & content creation, built together w. @sanofi and @OpenAI. We believe AI systems like Muse will enable us to drastically reduce cost + time of bringing new medicines to patients.

Honored to be part of @endpts list of top 11 most promising biopharmas! We're laser focused on bringing new treatments to patients faster and more efficiently by building a tech and AI driven pharma company. Join us:

RT @svangel: We’re thrilled to be partnering with the @formationbio team! Formation Bio is building a tech and AI-native pharma company dif…

RT @a16z: We are excited to lead the latest round in @formationbio, an AI-native pharma company going after the major bottleneck in drug de…

RT @BenjamineYLiu: Excited to announce our $372MM Series D financing, led by @a16z with major participation from @sanofi. Existing + new in…

Today we announce our $372MM Series D financing, led by @a16z with major participation from @sanofi, advancing our mission to bring new treatments to patients faster and more efficiently. Read more here!

We are excited to announce our collaboration with @OpenAI & @sanofi to build fine-tuned and custom AI solutions to transform drug development, advancing our mission to bring new treatments to patients faster and more efficiently.

RT @BenjamineYLiu: We are excited for TrialSpark to rebrand as @formationbio as we build the pharma company of the future that will acceler…

@TrialSpark has licensed sprifermin, an investigational first-in-class disease modifying treatment for osteoarthritis, from @merckgroup. Read more here about the transaction and TrialSpark's mission to bring new treatments to patients faster.

RT @BenjamineYLiu: After years of running trials for other drugmakers, TrialSpark is building its own pipeline -

We're super excited to share that TrialSpark has raised a $156M Series C to support our mission to bring new treatments to patients faster and more efficiently.

Did you catch @BenjamineYLiu's @ConferenceForum talk this week? If you’re interested in learning more about our decentralized, fully remote capabilities, reach out to our team at sponsors@trialspark.com or book time with us here: